These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 25287388)

  • 1. Physical stabilization of low-molecular-weight amorphous drugs in the solid state: a material science approach.
    Qi S; McAuley WJ; Yang Z; Tipduangta P
    Ther Deliv; 2014 Jul; 5(7):817-41. PubMed ID: 25287388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging trends in the stabilization of amorphous drugs.
    Laitinen R; Löbmann K; Strachan CJ; Grohganz H; Rades T
    Int J Pharm; 2013 Aug; 453(1):65-79. PubMed ID: 22569230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.
    Löbmann K; Grohganz H; Laitinen R; Strachan C; Rades T
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):873-81. PubMed ID: 23537574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
    Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stabilisation of amorphous ibuprofen in Upsalite, a mesoporous magnesium carbonate, as an approach to increasing the aqueous solubility of poorly soluble drugs.
    Zhang P; Forsgren J; Strømme M
    Int J Pharm; 2014 Sep; 472(1-2):185-91. PubMed ID: 24950364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amino acids as co-amorphous stabilizers for poorly water-soluble drugs--Part 2: molecular interactions.
    Löbmann K; Laitinen R; Strachan C; Rades T; Grohganz H
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):882-8. PubMed ID: 23567485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Theory and practice of supersaturatable formulations for poorly soluble drugs.
    Kawakami K
    Ther Deliv; 2015 Mar; 6(3):339-52. PubMed ID: 25853309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Refining stability and dissolution rate of amorphous drug formulations.
    Grohganz H; Priemel PA; Löbmann K; Nielsen LH; Laitinen R; Mullertz A; Van den Mooter G; Rades T
    Expert Opin Drug Deliv; 2014 Jun; 11(6):977-89. PubMed ID: 24754747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In silico prediction of the solubility advantage for amorphous drugs - Are there property-based rules for drug discovery and early pharmaceutical development?
    Kuentz M; Imanidis G
    Eur J Pharm Sci; 2013 Feb; 48(3):554-62. PubMed ID: 23262058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rational excipient selection for co-amorphous formulations.
    Korhonen O; Pajula K; Laitinen R
    Expert Opin Drug Deliv; 2017 Apr; 14(4):551-569. PubMed ID: 27267873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced bioavailability of a poorly soluble VR1 antagonist using an amorphous solid dispersion approach: a case study.
    Kennedy M; Hu J; Gao P; Li L; Ali-Reynolds A; Chal B; Gupta V; Ma C; Mahajan N; Akrami A; Surapaneni S
    Mol Pharm; 2008; 5(6):981-93. PubMed ID: 19434920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in co-amorphous drug formulations.
    Dengale SJ; Grohganz H; Rades T; Löbmann K
    Adv Drug Deliv Rev; 2016 May; 100():116-25. PubMed ID: 26805787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system.
    Pouton CW
    Eur J Pharm Sci; 2006 Nov; 29(3-4):278-87. PubMed ID: 16815001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Solid molecular dispersions of poorly water-soluble drugs in poly(2-hydroxyethyl methacrylate) hydrogels.
    Zahedi P; Lee PI
    Eur J Pharm Biopharm; 2007 Mar; 65(3):320-8. PubMed ID: 17182231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solid dispersions, part I: recent evolutions and future opportunities in manufacturing methods for dissolution rate enhancement of poorly water-soluble drugs.
    Bikiaris DN
    Expert Opin Drug Deliv; 2011 Nov; 8(11):1501-19. PubMed ID: 21919807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug polymorphism and dosage form design: a practical perspective.
    Singhal D; Curatolo W
    Adv Drug Deliv Rev; 2004 Feb; 56(3):335-47. PubMed ID: 14962585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melt extrusion with poorly soluble drugs.
    Shah S; Maddineni S; Lu J; Repka MA
    Int J Pharm; 2013 Aug; 453(1):233-52. PubMed ID: 23178213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of oral bioavailability of an HIV-attachment inhibitor by nanosizing and amorphous formulation approaches.
    Fakes MG; Vakkalagadda BJ; Qian F; Desikan S; Gandhi RB; Lai C; Hsieh A; Franchini MK; Toale H; Brown J
    Int J Pharm; 2009 Mar; 370(1-2):167-74. PubMed ID: 19100319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Miniaturized screening of polymers for amorphous drug stabilization (SPADS): rapid assessment of solid dispersion systems.
    Wyttenbach N; Janas C; Siam M; Lauer ME; Jacob L; Scheubel E; Page S
    Eur J Pharm Biopharm; 2013 Aug; 84(3):583-98. PubMed ID: 23395968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In situ amorphisation of indomethacin with Eudragit® E during dissolution.
    Priemel PA; Laitinen R; Grohganz H; Rades T; Strachan CJ
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1259-65. PubMed ID: 24056054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.